Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Restoring cefepime activity against multidrug-resistant KPC-producing by combination with boronic acid inhibitors, MB076 and S02030.
Antimicrob Agents Chemother
January 2025
Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Foremost in the design of new β-lactamase inhibitors (BLIs) are the boronic acid transition state inhibitors (BATSIs). Two highly potent BATSIs being developed are S02030 and MB076 strategically designed to be active against cephalosporinases and carbapenemases, especially KPC. When combined with cefepime, S02030 and MB076 demonstrated potent antimicrobial activity against laboratory and clinical strains of expressing a variety of class A and class C β-lactamases, including and .
View Article and Find Full Text PDFClinical, Microbiological Profile, and Treatment Outcomes of Carbapenem-Resistant Urinary Tract Infections in a Tertiary Care Hospital.
Indian J Nephrol
July 2024
Department of Nephrology, M S Ramaiah Medical College, Bangalore, India.
Background: Carbapenem-resistant urinary tract infections (CR-UTIs) are a major global health threat. Many factors contribute to the increasing incidence of CR-UTI. Owing to the limited availability of treatment options, CR-UTIs are highly challenging to treat.
View Article and Find Full Text PDFClinical Characteristics and Risk Factors for Multidrug-Resistant Complex Bacteremia in a Chinese Tertiary Hospital: A Decade Review (2013-2022).
Infect Drug Resist
January 2025
Department of Laboratory Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
Objective: This study aimed to analyze the antimicrobial resistance profiles, clinical characteristics and risk factors of bacteremia caused by complex (ECC) strains.
Methods: We retrospectively collected clinical data from patients diagnosed with ECC bacteremia between 2013 and 2022 in a tertiary hospital in Jiangsu. Subgroup analyses were performed based on multidrug resistance (MDR), nosocomial acquisition, polymicrobial bacteremia, and mortality.
Antimicrobial susceptibility of gram-negative bacteria: analysis from patients in a laboratory network in Brazil.
J Glob Antimicrob Resist
January 2025
Grupo Fleury, São Paulo, Brazil.
Objectives: This study aimed to describe the epidemiology and antimicrobial susceptibility patterns of gram-negative pathogens in Brazil from 2018 to 2020, addressing the gap in national data on healthcare-associated infections, using information from a private laboratory network.
Methods: A cross-sectional study was conducted using a database from Fleury hospital network, a private laboratory in Brazil. The analysis included blood, urine, and lower respiratory tract samples collected from January 2018 to June 2020.
Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Infections: A Multicenter Cohort Study.
Pharmaceuticals (Basel)
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Ha'il, P.O. Box 6166, Hail 81442, Saudi Arabia.
To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) infections. This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR infections. Outcomes were compared using multivariate logistic regression analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!